Best Peptides for Weight Loss: What the Research Shows
Written by NorthPeptide Research Team | Reviewed March 31, 2026
What Does the Research Say About Peptides and Weight Loss?
The past five years have transformed the weight loss landscape. GLP-1 receptor agonists like semaglutide and tirzepatide made international headlines with clinical trial results showing unprecedented fat loss — and they opened the door to an entire class of peptides being studied for metabolic function.
But semaglutide and tirzepatide are just the beginning. Researchers are now investigating a growing list of peptides that target fat metabolism through entirely different mechanisms — from triple-receptor agonists to mitochondrial peptides to enzyme inhibitors.
This article breaks down what published clinical trials and peer-reviewed research actually show about peptides studied for weight and fat loss. Every claim below is sourced from published data. No hype — just science.
1. Retatrutide — The Triple Agonist
What It Is
Retatrutide (LY3437943) is a triple agonist that activates GIP, GLP-1, and glucagon receptors simultaneously. While semaglutide targets one receptor and tirzepatide targets two, retatrutide hits all three — making it one of the most closely watched compounds in metabolic research.
What the Clinical Trials Show
In a Phase 2 trial published in The New England Journal of Medicine (Jastreboff et al., 2023), participants receiving the highest dose (12 mg) of retatrutide achieved a mean body weight reduction of 24.2% at 48 weeks. This was the largest weight reduction reported for any anti-obesity compound in a Phase 2 trial at the time of publication.
The study enrolled 338 adults with obesity (BMI ≥ 30) or overweight with at least one weight-related comorbidity. The triple-receptor mechanism is believed to enhance energy expenditure through the glucagon receptor while simultaneously reducing appetite through the GLP-1 and GIP pathways.
Phase 3 trials (the TRIUMPH program, sponsored by Eli Lilly) are currently underway to confirm these findings in larger populations.
Why Researchers Are Watching
The 24.2% figure puts retatrutide ahead of both semaglutide (14.9%) and tirzepatide (20.9%) from their respective Phase 2/3 trials — though direct head-to-head comparisons have not been published.
2. Semaglutide — The GLP-1 Benchmark
What It Is
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes (marketed as Ozempic) and later approved for chronic weight management (marketed as Wegovy). It is the most extensively studied peptide for weight loss.
What the Clinical Trials Show
The landmark STEP 1 trial, published in The New England Journal of Medicine (Wilding et al., 2021), studied 2.4 mg subcutaneous semaglutide in 1,961 adults with obesity over 68 weeks:
- Mean weight loss: 14.9% of body weight
- Approximately one-third of participants lost ≥ 20% of body weight
- Placebo group: 2.4% weight loss
Additional STEP trials confirmed these results across different populations:
- STEP 2 (type 2 diabetes patients): 9.6% weight loss at 68 weeks (The Lancet, 2021)
- STEP 3 (with behavioral therapy): 16.0% weight loss (JAMA, 2021)
- STEP 5 (long-term, 104 weeks): 15.2% sustained weight loss (Nature Medicine, 2022)
The SELECT trial (NEJM, November 2023) also demonstrated a 20% reduction in major adverse cardiovascular events, establishing benefits beyond weight loss alone.
Why Researchers Are Watching
Semaglutide set the modern benchmark for peptide-based weight management research. It demonstrated that targeting GLP-1 receptors could produce clinically meaningful and sustained weight reduction — paving the way for every compound on this list.
3. Tirzepatide — The Dual Agonist
What It Is
Tirzepatide is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly. It is marketed as Mounjaro (for type 2 diabetes) and Zepbound (for weight management, FDA-approved November 2023).
What the Clinical Trials Show
The SURMOUNT-1 Phase 3 trial, published in The New England Journal of Medicine (Jastreboff et al., 2022), studied 2,539 adults with obesity without diabetes over 72 weeks:
- 5 mg dose: 15.0% weight loss
- 10 mg dose: 19.5% weight loss
- 15 mg dose: 20.9% weight loss
- Placebo: 3.1% weight loss
SURMOUNT-3, which combined tirzepatide with intensive lifestyle intervention, showed reductions of up to 26.6% body weight at the highest dose.
Why Researchers Are Watching
Tirzepatide demonstrated that adding a second receptor target (GIP) on top of GLP-1 could produce greater weight loss than GLP-1 alone. This dual-agonist approach directly informed the development of triple agonists like retatrutide.
4. Survodutide — GLP-1 Meets Glucagon
What It Is
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Unlike tirzepatide (which pairs GLP-1 with GIP), survodutide pairs GLP-1 with glucagon — a hormone that increases energy expenditure and promotes fat oxidation.
What the Clinical Trials Show
In a Phase 2 trial published in The New England Journal of Medicine (Blüher et al., 2024), participants on the highest dose (4.8 mg) achieved 18.7% body weight loss at 46 weeks.
Notably, survodutide has also shown significant reductions in liver fat in a separate Phase 2 trial in patients with MASH (metabolic dysfunction-associated steatohepatitis), suggesting metabolic benefits beyond weight loss. Phase 3 trials (the SYNCHRONIZE program) are currently underway.
Why Researchers Are Watching
The glucagon component may offer advantages in fat oxidation and energy expenditure that GIP-based dual agonists don’t provide. The liver fat data adds a second potential clinical application.
5. Mazdutide — The Dual Agonist From China
What It Is
Mazdutide (LY3305677/IBI362) is another dual GLP-1 and glucagon receptor agonist, developed by Innovent Biologics in partnership with Eli Lilly. It was approved in China for type 2 diabetes in July 2024.
What the Clinical Trials Show
A Phase 2 trial published in The Lancet Diabetes & Endocrinology (2024) showed approximately 14.4% body weight loss at the 9 mg dose over 48 weeks in Chinese adults with obesity. Phase 3 trials (the GLORY program) are underway for the obesity indication.
Why Researchers Are Watching
Mazdutide shares the GLP-1/glucagon dual mechanism with survodutide but represents a different molecular approach. The approval in China for diabetes signals regulatory momentum for this class of dual agonists.
6. AOD-9604 — The Growth Hormone Fragment
What It Is
AOD-9604 is a modified fragment of human growth hormone (amino acids 177–191). It was designed to replicate the fat-metabolizing properties of growth hormone without its growth-promoting or blood sugar–elevating effects.
What the Research Shows
Early-phase studies conducted by Metabolic Pharmaceuticals (Australia) in the early 2000s investigated AOD-9604’s effect on body weight. The compound demonstrated lipolytic activity in preclinical models, stimulating fat breakdown through a mechanism independent of the growth hormone receptor.
However, clinical results have been modest. A Phase 2b trial did not achieve statistically significant weight loss compared to placebo over 24 weeks. No large-scale Phase 3 trials have been published.
Current Research Status
AOD-9604 remains an active area of research interest due to its targeted mechanism — specifically acting on fat tissue without the broader hormonal effects of full-length growth hormone. Researchers continue to investigate its potential in combination protocols and its effects on specific fat depots.
7. MOTS-c — The Mitochondrial Peptide
What It Is
MOTS-c is a mitochondria-derived peptide discovered by Changhan David Lee and colleagues at the University of Southern California. Unlike the GLP-1-based peptides above, MOTS-c works at the cellular energy level — regulating metabolic homeostasis through AMPK activation, the same pathway targeted by metformin.
What the Research Shows
The foundational study, published in Cell Metabolism (Lee et al., 2015), demonstrated that MOTS-c prevented diet-induced obesity in mouse models and improved insulin sensitivity — even when administered to already-obese subjects. The mechanism involves regulation of the folate-methionine cycle and activation of AMPK signaling.
Observational human data (2023) has shown that circulating MOTS-c levels are inversely correlated with obesity and insulin resistance — meaning people with lower natural MOTS-c levels tend to have higher body fat and worse metabolic markers.
No large-scale human clinical trials for weight loss have been completed as of the time of writing.
Why Researchers Are Watching
MOTS-c represents a fundamentally different approach to metabolic research — targeting mitochondrial function rather than appetite or receptor signaling. Its AMPK-activating mechanism positions it alongside metformin as a potential metabolic regulator, but through a peptide-based pathway.
8. 5-Amino-1MQ — The NNMT Inhibitor
What It Is
5-Amino-1MQ is a small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme linked to fat cell expansion and metabolic dysfunction. When NNMT is overactive, it depletes NAD+ and SAM — two molecules critical for cellular energy metabolism. By blocking NNMT, 5-Amino-1MQ aims to restore healthy cellular energy expenditure.
What the Research Shows
Preclinical research published in Biochemical Pharmacology (Neelakantan et al., 2018) demonstrated that in diet-induced obese mice, 5-Amino-1MQ treatment reduced body weight by approximately 7% and reduced fat mass by approximately 30% over just 11 days — without changes in food intake or loss of lean muscle mass.
The selectivity of the fat loss (preserving lean mass while reducing fat) is a key point of research interest. No human clinical trials have been published as of the time of writing.
Why Researchers Are Watching
The NNMT pathway is entirely different from GLP-1 receptor signaling. If the preclinical results translate to humans, 5-Amino-1MQ could offer a mechanism that specifically targets fat metabolism at the enzymatic level — potentially complementing rather than competing with receptor-based approaches.
9. Tesamorelin — The Visceral Fat Specialist
What It Is
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog. It is the only peptide on this list with FDA approval for a fat-reduction indication — specifically approved in 2010 for reduction of excess abdominal fat in HIV-associated lipodystrophy (marketed as Egrifta).
What the Clinical Trials Show
Pivotal trials published in The New England Journal of Medicine (Falutz et al., 2010) demonstrated:
- 15.2% reduction in visceral adipose tissue (VAT) at 26 weeks
- Placebo group: +5.0% increase in VAT
- Extension studies (52 weeks): maintained 18% visceral fat reduction
A follow-up study published in The Journal of Clinical Endocrinology & Metabolism (2014) showed tesamorelin also significantly reduced liver fat in the same patient population.
Important distinction: tesamorelin specifically targets visceral (deep abdominal) fat. It did not produce significant reductions in subcutaneous fat or overall body weight in these trials. Its mechanism works through stimulating natural growth hormone release, which in turn promotes visceral fat mobilization.
Why Researchers Are Watching
Visceral fat is the most metabolically dangerous type of fat — strongly associated with cardiovascular disease, type 2 diabetes, and metabolic syndrome. A compound that selectively reduces visceral fat has a distinct research profile from general weight loss agents.
10. CJC-1295 + Ipamorelin — The GH Secretagogue Stack
What It Is
CJC-1295 is a long-acting growth hormone-releasing hormone (GHRH) analog. Ipamorelin is a selective growth hormone secretagogue (ghrelin receptor agonist). Researchers frequently study them in combination because they stimulate growth hormone release through complementary pathways — CJC-1295 amplifies the signal while ipamorelin triggers the pulse.
What the Research Shows
CJC-1295 was shown to produce sustained elevation of growth hormone and IGF-1 levels for 6–14 days after a single injection, published in The Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006).
Ipamorelin demonstrated dose-dependent growth hormone release with a notably clean profile — minimal effects on cortisol or prolactin, unlike older GH secretagogues. This was published in the European Journal of Endocrinology (Raun et al., 1999).
The body composition rationale: elevated growth hormone is associated with increased lipolysis (fat breakdown) and preservation of lean mass. However, no large-scale published clinical trial has specifically studied the CJC-1295/Ipamorelin combination for weight or fat loss outcomes.
Why Researchers Are Watching
The combination targets body composition through the growth hormone axis rather than appetite suppression or receptor agonism. The evidence base is primarily pharmacokinetic (showing GH elevation) rather than outcome-based (showing fat loss), making it an area where more clinical research is needed.
How These Peptides Compare: A Research Summary
| Compound | Mechanism | Key Finding | Evidence Level | Source |
|---|---|---|---|---|
| Retatrutide | Triple agonist (GIP/GLP-1/Glucagon) | 24.2% body weight loss | Phase 2 (NEJM) | Jastreboff et al., 2023 |
| Tirzepatide | Dual agonist (GIP/GLP-1) | 20.9% body weight loss | Phase 3 (NEJM) | Jastreboff et al., 2022 |
| Survodutide | Dual agonist (GLP-1/Glucagon) | 18.7% body weight loss | Phase 2 (NEJM) | Blüher et al., 2024 |
| Semaglutide | GLP-1 agonist | 14.9% body weight loss | Phase 3 (NEJM) | Wilding et al., 2021 |
| Mazdutide | Dual agonist (GLP-1/Glucagon) | 14.4% body weight loss | Phase 2 (Lancet D&E) | 2024 |
| Tesamorelin | GHRH analog | 15.2% visceral fat reduction | FDA-approved (NEJM) | Falutz et al., 2010 |
| AOD-9604 | GH fragment (lipolytic) | Preclinical lipolytic activity | Phase 2b (inconclusive) | Metabolic Pharma, ~2007 |
| MOTS-c | Mitochondrial / AMPK | Prevented obesity in mice | Preclinical (Cell Metab) | Lee et al., 2015 |
| 5-Amino-1MQ | NNMT inhibitor | 30% fat mass reduction in mice | Preclinical (Biochem Pharmacol) | Neelakantan et al., 2018 |
| CJC-1295 + Ipamorelin | GH secretagogues | Sustained GH/IGF-1 elevation | Phase 1 / PK data | Teichman et al., 2006 |
What This Means for Research
The metabolic peptide landscape is broader and more varied than the headlines suggest. While GLP-1 agonists dominate mainstream coverage, researchers are actively investigating compounds that work through entirely different mechanisms — from mitochondrial signaling (MOTS-c) to enzymatic inhibition (5-Amino-1MQ) to targeted visceral fat reduction (tesamorelin).
The key takeaway from the published data: no single mechanism has proven to be the definitive approach. The most promising clinical results have come from multi-receptor agonists (retatrutide, tirzepatide, survodutide), but the preclinical data on NNMT inhibition and mitochondrial peptides suggests that the next generation of metabolic research may look very different from the current GLP-1 era.
All compounds discussed in this article are the subject of ongoing research. Published trial data represents specific study populations and controlled conditions. Individual research applications should be designed with appropriate protocols and oversight.
Frequently Asked Questions
What peptide showed the highest weight loss in clinical trials?
According to published clinical trial data, retatrutide demonstrated the highest mean body weight reduction at 24.2% in a Phase 2 trial published in The New England Journal of Medicine (2023). However, Phase 3 data is still pending, and direct head-to-head comparisons between peptides have not been conducted.
What is the difference between GLP-1 agonists and other metabolic peptides?
GLP-1 agonists (like semaglutide) primarily work by mimicking the incretin hormone GLP-1, which reduces appetite and slows gastric emptying. Other peptides studied for metabolic function work through entirely different mechanisms — MOTS-c targets mitochondrial energy production, 5-Amino-1MQ inhibits a fat-storage enzyme, and tesamorelin stimulates growth hormone release to mobilize visceral fat.
Are these peptides FDA-approved for weight loss?
Semaglutide (as Wegovy) and tirzepatide (as Zepbound) are FDA-approved for chronic weight management. Tesamorelin (as Egrifta) is FDA-approved for reduction of visceral fat in HIV-associated lipodystrophy. All other peptides discussed in this article are in various stages of clinical or preclinical research and are not FDA-approved for weight management.
What does “preclinical” mean vs “Phase 2” or “Phase 3”?
Preclinical research is conducted in laboratory settings and animal models before human testing begins. Phase 2 trials test efficacy and dosing in a few hundred participants. Phase 3 trials are large-scale studies (often thousands of participants) required for regulatory approval. Compounds with Phase 3 data (semaglutide, tirzepatide) have the strongest evidence base; compounds with only preclinical data (MOTS-c, 5-Amino-1MQ) have the most to prove.
Products mentioned in this article: